Changes in function of drug transporters in the kidneys alter susceptibility of patients to adverse events such as cisplatin-induced renal injury. We have demonstrated that the rodent and human Mrp2 transporter participates in the secretion of cisplatin into urine and protects against nephrotoxicity.
Identification of novel biomarkers of subclinical nephrotoxicity in cancer patients. We are screening 12 biomarkers for their ability to detect cisplatin nephrotoxicity in cancer patients earlier and to a more sensitive degree than traditional laboratory markers.
Wen X, Buckley B, McCandlish E, Manautou J, Goedken M, Aleksunes L (2014) Mrp2 reduces the renal accumulation of cisplatin and protects against nephrotoxicity in wild-type and humanized mice. Am J Pathol. 184:1299-308.
Bircsak K, Gibson C, Robey R, Aleksunes L (2013) Assessment of transporter function using fluorescent cell imaging. Current Protocols in Toxicology. Unit 23.6.1-23.6.15. Invited manuscript.
Klaassen C, Aleksunes L (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Invited Review for Pharm. Rev. 62:1-96.
Aleksunes L, Goedken M, Rockwell C, Thomale J, Manautou J, Klaassen C (2010) Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther. 335:2-12.